Ocean Biomedical (formerly known as Aesther Healthcare Acquisition) is a biopharmaceutical company that focuses on medical research in oncology, fibrosis, infectious disease, and inflammation. It develops a mono-specific and two bi-specific humanized monoclonal antibodies for the treatment of non-small cell lung cancer and glioblastoma multiforme and a molecule product candidate for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome. The company partners with scientists and research institutions.